A primary stent-graft is deployed into a primary vessel to exclude an aneurysm. To maintain perfusion to a branch vessel covered by the primary stent-graft, a gutter filling stent-graft is deployed in parallel to the primary stent-graft. The gutter filling stent-graft includes a balloon that is pressurized and inflated by the patient's own blood thereby sealing any gutters formed around the gutter filling stent-graft. By sealing the gutters, the chance of type I endoleaks, migrations, and overall failure to exclude the aneurysm is minimized.

Disclosed are balloon catheters for forming liquid cast biodegradable arterial stents, typically, the balloon catheters include multiple balloons and multiple ports and include an element for promoting or initiating curing of a polymer solution via polymerization or cross-linking.

Disclosed are balloon catheters for forming liquid cast biodegradable arterial stents, typically, the balloon catheters include multiple balloons and multiple ports and include an element for promoting or initiating curing of a polymer solution via polymerization or cross-linking.

In one embodiment according to the present invention, a stent is described having a generally cylindrical body formed from a single woven nitinol wire. The distal and proximal ends of the stent include a plurality of loops, some of which include marker members used for visualizing the position of the stent. In another embodiment, the previously described stent includes an inner flow diverting layer.

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

The invention relates to a tubular sleeve for the atraumatic treatment of hollow organs, wherein the sleeve is folded in an initial state and can be unfolded in order to lie against an inner wall of a hollow organ in a final state. The sleeve is characterized in that the sleeve is formed of an outer wall and an inner wall, which are arranged concentrically to each other, wherein the outer wall and the inner wall are tightly connected to each other at ends thereof in such a way that an approximately tubular compartment is formed in the region between the outer wall and the inner wall and the folding of the sleeve is directed about a sleeve longitudinal axis.

The invention relates to a tubular sleeve for the atraumatic treatment of hollow organs, wherein the sleeve is folded in an initial state and can be unfolded in order to lie against an inner wall of a hollow organ in a final state. The sleeve is characterized in that the sleeve is formed of an outer wall and an inner wall, which are arranged concentrically to each other, wherein the outer wall and the inner wall are tightly connected to each other at ends thereof in such a way that an approximately tubular compartment is formed in the region between the outer wall and the inner wall and the folding of the sleeve is directed about a sleeve longitudinal axis.

Expandable endograft devices, systems, and methods of using the same to partially or fully occlude a luminal organ. An endograft device described herein may include a stent portion and a wall portion, wherein the wall portion is configured to receive a substance therein.

An embodiment includes a process for treating an abdominal aortic aneurysm (AAA) endoleak with a shape memory polymer (SMP) foam device. First, a bifurcated stent graft is placed within the aneurysm while a micro guidewire is positioned within the aneurysm for future catheter access. Second, after placing the iliac graft extension, a catheter is introduced over wire to deliver embolic foams. Third, embolic foams expand and conform to the aneurysm wall. Fourth, embolic foams create a stable thrombus to prevent endoleak formation by isolating peripheral vessels from the aneurysm volume.

An embodiment includes a process for treating an abdominal aortic aneurysm (AAA) endoleak with a shape memory polymer (SMP) foam device. First, a bifurcated stent graft is placed within the aneurysm while a micro guidewire is positioned within the aneurysm for future catheter access. Second, after placing the iliac graft extension, a catheter is introduced over wire to deliver embolic foams. Third, embolic foams expand and conform to the aneurysm wall. Fourth, embolic foams create a stable thrombus to prevent endoleak formation by isolating peripheral vessels from the aneurysm volume.